|
Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Final results and exploratory biomarker analysis from the phase 2 TRICOTEL study. |
|
|
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME |
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax ; MSD; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Sanofi; Sun Pharma; T3 Pharmaceuticals; Takeda; touchIME |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst) |
|
|
Stock and Other Ownership Interests - Oncobit |
Consulting or Advisory Role - Oncobit |
Research Funding - Novartis; Oncobit; Roche; Scailyte |
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Genentech/Roche |
|
|
Employment - F. Hoffmann LaRoche |
Honoraria - F. Hoffmann LaRoche |
|
|
No Relationships to Disclose |
|
|
|
|
|
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Jazz Pharmaceuticals; Karyopharm Therapeutics; Medicenna; Merck; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst) |